Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 45 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Peel Clear all
Completed Phase 2 Interventional Results available

Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis

NCT00770965
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
AIN457, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Santa Monica, California • Louisville, Kentucky • High Point, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 16, 2026, 6:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Satiety, Glycemic, and Gastrointestinal Effects of Novel Fibers

NCT00958399
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Resistant Starch, Resistant starch + soluble fiber, Fiber made from corn starch, Fiber made from corn starch + soluble fiber
Dietary Supplement
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Oct 16, 2026, 6:27 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

The Efficacy of Systemic Valacyclovir (Valtrex) on Periodontitis

NCT05712343
View directory record Official record
Conditions
Severe Periodontitis
Interventions
Valacyclovir group, Control group
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 16, 2026, 6:27 PM EDT
Terminated Phase 2 Interventional

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

NCT04311515
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo
Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 16, 2026, 6:27 PM EDT
Completed Early Phase 1 Interventional

Effect of Enamel Matrix Proteins on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients

NCT02972788
View directory record Official record
Conditions
Periodontal Bone Loss
Interventions
Enamel Matrix Proteins Derivative, Saline
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 16, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Results available

Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite

NCT04996264
View directory record Official record
Conditions
Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake
Interventions
Varespladib Methyl, Placebo, Standard of care (SOC)
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
5 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Tucson, Arizona • Loma Linda, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 16, 2026, 6:27 PM EDT
Recruiting Phase 2 Interventional

LIFT: Life Improvement Trial

NCT06366724
View directory record Official record
Conditions
ME/CFS, Long COVID, PASC
Interventions
Pyridostigmine, Low-Dose Naltrexone, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 6:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Novel Supplement on Glycemic Variability Measured by Continuous Glucose Monitoring

NCT05832463
View directory record Official record
Conditions
Healthy
Interventions
Carbohydrate blocking supplement (CBS), Placebo capsule
Dietary Supplement
Lead sponsor
dōTERRA International
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pleasant Grove, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 16, 2026, 6:27 PM EDT
Recruiting Not applicable Interventional

An Evaluation of the Effect of the Erchonia FX-405 Laser as an Adjunctive Treatment of Periodontitis

NCT06656325
View directory record Official record
Conditions
Periodontal Diseases, Periodontitis, Gum Disease
Interventions
Erchonia® FX405, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
22 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Thousand Oaks, California • Acton, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 16, 2026, 6:27 PM EDT
Completed Phase 2 Interventional

Treating Periodontal Infection: Effects on Glycemic

NCT00016835
View directory record Official record
Conditions
Periodontal Disease, Diabetes Mellitus, Type 2
Interventions
Supra-gingival scaling and placebo, Subgingival scaling and metronidazole, Subgingival scaling and doxycycline
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 16, 2026, 6:27 PM EDT
Terminated Phase 4 Interventional

Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD

NCT01778647
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Stimulants plus Lovaza, Stimulants plus placebo
Dietary Supplement · Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
6 Years to 15 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 16, 2026, 6:27 PM EDT
Completed Phase 3 Interventional

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Vascular Access Procedures in Children

NCT00125255
View directory record Official record
Conditions
Pain
Interventions
S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%), Placebo Peel
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 16, 2026, 6:27 PM EDT
Completed Phase 3 Interventional

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Laser-Assisted Tattoo Removal in Adults

NCT00110734
View directory record Official record
Conditions
Pain
Interventions
S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2005 · Synced Oct 16, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Results available

Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus

NCT03336398
View directory record Official record
Conditions
Tinnitus
Interventions
Ketamine Hydrochloride in saline
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 16, 2026, 6:27 PM EDT
Recruiting Phase 2 Interventional

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

NCT07284667
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
Interventions
ACP-211, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Chino, California • Glendale, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 16, 2026, 6:27 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Investigating the Effectiveness of 2 Different Doses of BIOHM FX Probiotic Blend in Improving Digestive Symptoms

NCT06782945
View directory record Official record
Conditions
Moderate Gastrointestinal Discomfort
Interventions
BIOHM FX Probiotic Blend
Dietary Supplement
Lead sponsor
Biohm Technologies
Industry
Eligibility
18 Years to 75 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 16, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Results available

Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers

NCT00066066
View directory record Official record
Conditions
Periodontitis, Periodontal Diseases
Interventions
Scaling and root planing, Metronidazole, Amoxicillin, Doxycycline
Procedure · Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
20 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 16, 2026, 6:27 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis

NCT02313883
View directory record Official record
Conditions
Periodontitis
Interventions
PerioSept(r)
Drug
Lead sponsor
Geistlich Pharma AG
Industry
Eligibility
18 Years to 74 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
4
States / cities
Fullerton, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 16, 2026, 6:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Placebo-Controlled Study Assessing the Use of a Novel Exfoliative Serum With A Chemical Peel to Improve Photodamage in Adults

NCT05908825
View directory record Official record
Conditions
Photodamaged Skin
Interventions
Vitamin C with AHA Exfoliative Serum, Placebo serum
Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
30 Years to 65 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 16, 2026, 6:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changes in Metabolic Rate and Perceptual Indicators After Acute Ingestion of Paraxanthine

NCT05811923
View directory record Official record
Conditions
Metabolic Syndrome, Caffeine
Interventions
Venous Blood Collection, Resting Metabolic Rate Determination, Mood State, Visual Analog Scales
Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 16, 2026, 6:27 PM EDT
Completed Phase 3 Interventional

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Skin Filler Injection in the Face

NCT00110760
View directory record Official record
Conditions
Pain
Interventions
S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%), Placebo Peel
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
3
States / cities
Englewood, Colorado • Nashville, Tennessee • Bryan, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 16, 2026, 6:27 PM EDT